摘要
在后基因组时代,随着分子病理检测技术的不断提高,肿瘤的预防与诊疗模式已发生显著变化,分子病理检测在实体肿瘤的全流程管理中的应用愈发深入,并逐渐成为提高实体肿瘤患者总体生存率的重要手段。近年来,以第二代测序技术为代表的分子病理检测在肿瘤遗传易感基因鉴定、泛实体肿瘤早期筛查与恶性实体肿瘤个体化治疗策略的制定等方面发挥重要作用。本文对不同分子病理检测平台在不同实体肿瘤防治阶段的实际应用场景及潜在问题进行概述。
In the post-genomic era,with the advancement of molecular pathological detection techniques,the mode of tumor prevention,diagnosis and treatment has changed dramatically.Molecular pathological detection techniques has been more and more used in the whole course management of solid tumors,and has become critical for promoting the overall survival of patients with solid tumors.In recently years,molecular pathological testing represented by next generation sequencing(NGS)has played key roles in identification of genetic susceptibility genes,early detection of solid tumors and development of personalized therapeutic strategies for malignant solid tumors.This review briefly introduces the real world application of different molecular pathological testing platforms in different stages of tumor prevention and management as well as the potential problems.
作者
温晋暄
Jinjuan Yao
刘泽兵
WEN Jinxuan;YAO Jinjuan;LIU Zebing(Department of Pathology,Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China;Department of Pathology and Laboratory Medicine,Memorial Sloan Kettering Cancer Center,New York,NY 10065,USA)
出处
《肿瘤》
CAS
北大核心
2023年第4期354-358,共5页
Tumor
基金
上海交通大学医学院-双百人项目(2022年度)
关键词
分子病理检测
实体肿瘤
肿瘤三级预防
Molecular pathological detection
Solid tumor
Tertiary prevention of tumor
作者简介
Correspondence to:刘泽兵,E-mail:zebing080@163.com
